Abu dhabi: Greek pharmaceuticals manufacturer, ELPEN, today announced the launch of its first MEA subsidiary in the United Arab Emirates. The move marks a major milestone in the company's international expansion strategy and strengthens its long-term commitment to improving healthcare across the region.
According to Emirates News Agency, with its new offices in the UAE, ELPEN's MEA subsidiary will serve as the company's regional strategic centre, enabling closer engagement with health authorities, clinicians, scientific communities, medical societies, and institutional partners across the region. Theodore Tryfon, Co-Chief Executive Officer of ELPEN Group, highlighted the company's dedication to aligning Greek scientific innovation with the UAE's healthcare advancements. He emphasized ELPEN's nearly six decades of experience in pharmaceutical manufacturing and its commitment to fostering collaborations that enhance patient access and support sustainable industry growth.
With the region experiencing rising demand for safe, trusted, and high-quality medicines, the new subsidiary positions ELPEN to operate with greater agility, cultural understanding, and proximity to the needs of local healthcare systems. The company has appointed Mohammad Allakany as General Manager for Middle East and Africa, bringing decades of healthcare experience and a proven leadership track record. In his role, he will oversee ELPEN's growth strategy and regional expansion across MEA.
Lefteris Tryfon, Chief Operating Officer of ELPEN Group, commented on the strategic significance of entering the UAE, stating that it represents a carefully planned move to establish a lasting presence in a region that values quality and scientific integrity. With ELPEN's international business set to double by 2028, the UAE is seen as a pivotal enabler of the company's regional presence, facilitating expanded access to high-quality treatments and improved health outcomes across the Middle East and Africa.